LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Elenco Azioni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

162.44 -3.79

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

159.29

Massimo

168.57

Metriche Chiave
By Trading Economics
Entrata	262M -15M
Vendite	1.6M 996M
EPS	2.06
Margine di Profitto	-1.486
Dipendenti	18,300
EBITDA	-11M 187M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+19.95% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-388M 8.1B
Apertura precedente	166.23
Chiusura precedente	162.44

Notizie sul Sentiment di mercato

By Acuity

18%

82%

39 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

117.16 / 144.77 Supporto e resistenza

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2026, 22:54 UTC

Utili

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 mag 2026, 23:17 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mag 2026, 23:16 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mag 2026, 23:15 UTC

Utili

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mag 2026, 23:14 UTC

Utili

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mag 2026, 23:02 UTC

Discorsi di Mercato

Utili

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mag 2026, 22:59 UTC

Discorsi di Mercato

Utili

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mag 2026, 22:24 UTC

Utili

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Revenue Growth 47%>XRO.AU

13 mag 2026, 22:22 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mag 2026, 22:18 UTC

Utili

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mag 2026, 22:16 UTC

Utili

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mag 2026, 22:13 UTC

Utili

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mag 2026, 22:12 UTC

Utili

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mag 2026, 22:09 UTC

Utili

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mag 2026, 22:00 UTC

Utili

Cisco to Shed Jobs for All-In AI Push -- Update

13 mag 2026, 21:11 UTC

Utili

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

19.95% in crescita

Previsioni per 12 mesi

Media 202.35 USD 19.95%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

39 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.